<SEC-DOCUMENT>0001161697-19-000455.txt : 20191023
<SEC-HEADER>0001161697-19-000455.hdr.sgml : 20191023
<ACCEPTANCE-DATETIME>20191023085549
ACCESSION NUMBER:		0001161697-19-000455
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20191023
DATE AS OF CHANGE:		20191023

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPRO MED SYSTEMS INC
		CENTRAL INDEX KEY:			0000704440
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133044880
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-229498
		FILM NUMBER:		191162798

	BUSINESS ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
		BUSINESS PHONE:		845-469-2042

	MAIL ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>prospectus_424b3-sup10.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT NO. 10 TO 424(B)(3)
<TEXT>
<HTML>
<HEAD>
</HEAD>
<TITLE></TITLE>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<DIV style="width:7.5in">
<BR>

<P style="margin:0px; font-size:12pt" align=right>Filed Pursuant to Rule 424(b)(3) </P>

<P style="margin:0px; font-size:12pt" align=right>Registration No. 333-229498</P>

<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P style="margin:0px; font-size:12pt" align=center>PROSPECTUS SUPPLEMENT NO. 10</P>

<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P style="margin:0px; font-size:12pt" align=center>(to Prospectus dated March 8, 2019)</P>

<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P style="margin:0px; font-size:12pt" align=center>REPRO MED SYSTEMS, INC.</P>

<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P style="margin:0px; font-size:12pt" align=center>11,101,697 shares of common stock</P>

<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P style="margin:0px; font-size:12pt; text-align: justify">This prospectus supplement No. 10 supplements and amends the
prospectus dated March 8, 2019, as supplemented by prospectus supplement No. 1, dated April 29, 2019, as further supplemented
by prospectus supplement No. 2, dated May 7, 2019, prospectus supplement No. 3, dated May 8, 2019, prospectus supplement No.
4, dated June 27, 2019, prospectus supplement No. 5, dated July 2, 2019, prospectus supplement No. 6, dated August 7, 2019,
prospectus supplement No. 7, dated September 4, 2019, prospectus supplement No. 8, dated October 1, 2019 and prospectus
supplement No. 9, dated October 14, 2019 (collectively, the &ldquo;Prospectus&rdquo;), which forms a part of our Registration
Statement on Form S-1 (Registration No. 333-229498). This prospectus supplement is being filed to update and supplement the
information in the Prospectus with information contained in our Current Report on Form 8-K filed with the Securities and
Exchange Commission on October 23, 2019 (the &ldquo;Current Report&rdquo;). Accordingly, we have attached the Current Report
to this prospectus supplement.</P>

<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P style="margin:0px; font-size:12pt; text-align: justify">The Prospectus and this prospectus supplement relate solely to
11,101,697 shares of Repro Med Systems, Inc. common stock, par value $0.01 per share, which we refer to as our common stock,
which may be offered for sale from time to time by the stockholders named under the heading &ldquo;Selling
Stockholders&rdquo; in the Prospectus.</P>

<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P style="margin:0px; font-size:12pt; text-align: justify">This prospectus supplement should be read in conjunction with the Prospectus, including any supplements or amendments thereto. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. &nbsp;This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements to it.</P>

<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P style="margin:0px; font-size:12pt; text-align: justify">Our common stock is currently listed on the NASDAQ Capital Market
under the symbol &ldquo;REPR.&rdquo; The closing price of our common stock as reported on the NASDAQ Capital Market on
October 21, 2019, was $4.08.</P>

<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P style="margin:0px; font-size:12pt; text-align: justify"><B>Investing in our common stock involves risks, and you should not invest unless you can afford to lose your entire investment. See the section entitled &ldquo;Risk Factors&rdquo; beginning on page 5 of the Prospectus. </B></P>

<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P style="margin:0px; font-size:12pt; text-align: justify"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P style="margin:0px; font-size:12pt" align=center><B>The date of this prospectus supplement is October 23, 2019.</B></P>

<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P style="margin:0" align=center><B>UNITED STATES</B></P>
<P style="margin:0" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin:0" align=center><B>Washington, DC 20549</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:12pt" align=center><B>FORM 8-K</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:12pt" align=center><B>CURRENT REPORT</B></P>
<P style="margin:0; font-size:12pt" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0" align=center>Date of Report (Date of earliest event reported)&nbsp;&nbsp;&nbsp;<B><U>October 23, 2019</U></B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:14pt" align=center><B><U>REPRO MED SYSTEMS, INC.</U></B></P>
<P style="margin:0" align=center>(Exact name of registrant as specified in its charter)</P>
<P style="margin:0" align=center>&nbsp;</P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 align=center>
<TR><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>New York</U></B></P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>0-12305</U></B></P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>13-3044880</U></B></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(State or other jurisdiction<BR>
of incorporation)</P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(Commission<BR>
File Number)</P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(IRS Employer<BR>
Identification No.)</P>
</TD></TR>
</TABLE>
<P style="margin:0" align=center><BR></P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 align=center>
<TR><TD style="margin-top:0" valign=top width=288><P style="margin:0" align=center><B><U>24 Carpenter Road, Chester, New York</U></B></P>
</TD><TD style="margin-top:0" valign=top width=96><P style="margin:0" align=center><B><U>10918</U></B></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top width=288><P style="margin:0" align=center>(Address of principal executive offices)</P>
</TD><TD style="margin-top:0" valign=top width=96><P style="margin:0" align=center>(Zip Code)</P>
</TD></TR>
</TABLE>
<P style="margin:0" align=center><BR></P>
<P style="margin:0" align=center>Registrant&rsquo;s telephone number, including area code&nbsp;&nbsp;&nbsp;<B><U>(845) 469-2042</U></B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0" align=center><U>not applicable</U></P>
<P style="margin:0" align=center>(Former name or former address, if changed since last report)</P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Emerging growth company &nbsp;[_]</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &nbsp;[_]</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Securities registered pursuant to Section 12(b) of the Act:</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-top: 0px; font-size: 10pt"><TR height=0 style="font-size:1pt"><TD STYLE="width: 2.5in"></TD><TD STYLE="width: 2.5in"></TD><TD STYLE="width: 2.5in"></TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Title of each class</U></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Trading symbol(s)</U></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Name of each exchange on which registered</U></P>
</TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><B>common stock, $0.01 par value</B></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><B>REPR</B></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><B>NASDAQ Capital Market</B></P>
</TD></TR>
</TABLE>
<P style="margin:0; text-align: justify">&nbsp;</P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P style="margin:0"><B>ITEM 8.01 OTHER EVENTS.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">Repro Med Systems, Inc. (the &ldquo;Company&rdquo;) is filing this Current Report
on Form 8-K to report that effective October 24, 2019, the Company will begin using a new dba name, &ldquo;KORU Medical
Systems&rdquo;, in place of &ldquo;RMS Medical Products&rdquo;. Reflecting this change, the Company&rsquo;s common stock will
commence trading under the new ticker symbol &ldquo;KRMD&rdquo; on the NASDAQ Capital Market effective October 24, 2019. On
October 24, 2019 the Company&rsquo;s email address will change to the domain@korumedical.com, and its home page will become
www.korumedical.com.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">On October 23, 2019, the Company issued a press release announcing the events set forth in this Current Report
on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 hereto.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0"><B>ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0; text-align: justify">(d) Exhibits.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 720px">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 96"><U>Exhibit No.</U></TD>
    <TD STYLE="width: 624"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>99.1</TD>
    <TD>Press release dated October 23, 2019</TD></TR>
</TABLE>
<P style="margin:0px; text-align: justify"><BR></P>
<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">- 2 -</P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P style="margin:0" align=center><B>SIGNATURES</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0; text-indent:0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 width=100%>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=360 colspan=2><P style="margin:0">REPRO MED SYSTEMS, INC.<BR>
(Registrant)</P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=24><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0">&nbsp;</P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">Date: &nbsp;<U>October 23, 2019</U></P>
</TD><TD style="margin-top:0" valign=top width=24><P style="margin:0">By:</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0"><U>/s/ Karen Fisher</U></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top colspan=2><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0">Karen Fisher<BR>
Chief Financial Officer and Secretary</P>
</TD></TR>
</TABLE>
<P style="margin:0"><BR></P>
<P style="margin:0" align=center>- 3 -</P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P style="margin:0px" align=center><B>Exhibit 99.1</B></P>

<P style="margin:0px">&nbsp;</P>

<P style="margin:0px"><img src="rms_logo.jpg"></P>

<P style="margin:0px">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>FOR IMMEDIATE RELEASE</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>RMS MEDICAL PRODUCTS ANNOUNCES REBRANDING TO KORU MEDICAL SYSTEMS</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>NEW TICKER SYMBOL &ldquo;KRMD&rdquo;</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>CHESTER, NY &ndash; October 23, 2019
- Repro Med Systems, Inc. (NASDAQ: REPR) (&ldquo;the Company&rdquo;)</B> today announced a new dba name, KORU Medical
Systems, which the Company will begin using in place of RMS Medical Products on October 24, 2019. Reflecting this change,
the Company&rsquo;s common stock will commence trading under the new ticker symbol &ldquo;KRMD&rdquo; on the NASDAQ effective
October 24, 2019.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Company announced the
rebranding on the eve of this year&rsquo;s Immunoglobulin National Society Conference (IgNS 2019) in Las Vegas, Nevada, a
unique, multi-disciplinary gathering of nurses, pharmacists, physicians, and Ig industry leaders.  The Company&rsquo;s management
team and board of directors will be attending IgNS 2019.</P>

<P STYLE="margin: 0">&ldquo;Our decision to rebrand the Company reflects the great strides we have made in evolving our corporate
culture, mission, and philosophy to a more patient-centric focus,&rdquo; said Don Pettigrew, President and CEO.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;The rebranding is inspired by the
koru, a widely recognized symbol of a spiral-shaped, unfurling fern that represents new life and new beginnings,&rdquo; said
Mr. Pettigrew.&nbsp; &ldquo;KORU Medical Systems&rsquo; focus on providing patients&rsquo; new beginnings with our at-home infusion
systems is at the heart of our brand.&rdquo;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 24, 2019 the Company&rsquo;s
email address will change to the domain @korumedical.com and its home page will become www.korumedical.com.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Committee on Uniform Securities
Identification Procedures (CUSIP) number assigned to the Company&rsquo;s common stock will remain the same.&nbsp; The dba name
change will not affect the rights of the Company&rsquo;s stockholders. The Company&rsquo;s corporate name, Repro Med Systems, Inc.,
will not change as a result of the dba name change at this time.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>About the Company</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company develops, manufactures and
commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the
world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60<SUP>&reg;</SUP> and FreedomEdge<SUP>&reg;</SUP>
Syringe Infusion Drivers, Precision Flow Rate Tubing<SUP>&trade;</SUP> and HIgH-Flo Subcutaneous Safety Needle
Sets<SUP>&trade;</SUP>. These devices are used for infusions administered in the home and alternate care settings.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Forward-Looking Statements</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The statements contained herein include
prospects, statements of future expectations and other forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that are based on management&rsquo;s current views and assumptions and involve known and
unknown risks and uncertainties, identified by words such as &ldquo;will.&rdquo; Actual results, performance or events may
differ materially from those expressed or implied in such forward-looking statements. Factors that may cause actual results
to differ materially from current expectations and other risks are discussed in the Company&rsquo;s filings with the U.S.
Securities and Exchange Commission, including its Annual Report on Form 10-K, which filings are available from the SEC and
the Company&rsquo;s website. The Company undertakes no obligation to update any forward-looking statements.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>Contacts:</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 179.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt"><B>The Equity Group Inc.</B></FONT></TD>
    <TD STYLE="width: 180.9pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">Devin Sullivan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">Kalle Ahl, CFA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">Senior Vice President</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">Vice President</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">212-836-9608</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">212-836-9614</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">mailto: dsullivan@equityny.com</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">kahl@equityny.com </FONT></TD></TR>
</TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR noshade align="center" width="100%" size="2">
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>rms_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 rms_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  P *H# 2(  A$! Q$!_\0
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MQ/\ LJ_&Z:8.=Y8/!>_"GXP7&F619XV_X1OXA,VC9)^)'P]T6,ZO]7?M??\
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M'5?#3>'M<TG5FU.]T30I;-I+^TN;,#3_ +7<_P 9WQ=_X(S?'WX$?L"_'O\
M;S_:[\6ZCX9^*5A/\+=1\*?!U]2C\7>-[[5OBM\<OAQX$UWQ?\>/'=]<ZOO\
M07&E>,=<U!?">BWVJZTFNS6&K>*?&%I>VNL^$+C]8O\ @D%X8\6>./\ @@C_
M ,%!O!/@*QO]3\<>+V_;4\,>$-,TI9)-5U3Q+KO[,_@[2]&TW2TA(E.I:A?W
M,%E8"%UE^USPF)T<!AZW$?AWX>8+@&./R+/*F>9Q@^.,BX4S?BJ$Z]#*(SS*
MI0IYE# 8626'J9;@:.*ABH8EU:E><\-4G5Q4XQE3,,)FN;5<T6'Q>'AA*-3
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M<(Q@^*AFN.Q5%5ZV?Y=@9U93DL)4PJA5H14Y*,*LI-N;T34DM5K+WG)'@/\
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?2V2N[1C=+W8JRCOI]J2LSJO?K?HGY+17OUTU\S__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
